TOP > 外国特許検索 > IgG-BINDING PEPTIDE

IgG-BINDING PEPTIDE UPDATE

外国特許コード F170009267
整理番号 (S2016-0552-N0)
掲載日 2017年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP010115
国際公開番号 WO 2017159655
国際出願日 平成29年3月14日(2017.3.14)
国際公開日 平成29年9月21日(2017.9.21)
優先権データ
  • 特願2016-049153 (2016.3.14) JP
発明の名称 (英語) IgG-BINDING PEPTIDE UPDATE
発明の概要(英語) [Problem] To provide a peptide that binds strongly to immunoglobulin G (IgG).
[Solution] This peptide has the amino acid sequence represented by SEQ ID NO:1. In said amino acid sequence: the 16th amino acid (X16) from the amino acid of the N-terminal is L, M, I or F; the 17th amino acid (X17) from the amino acid of the N-terminal is R, K, Y or Q; the 19th amino acid (X19) from the amino acid of the N-terminal is an arbitrary amino acid; the 20th amino acid (X20) from the amino acid of the N-terminal is an arbitrary amino acid; the 26th amino acid (X26) from the amino acid of the N-terminal is G or E, or is deleted; the 29th amino acid (X29) from the amino acid of the N-terminal is an arbitrary amino acid; the 30th amino acid (X30) from the amino acid of the N-terminal is an arbitrary amino acid; the 32nd amino acid (X32) from the amino acid of the N-terminal is an arbitrary amino acid; and the 33rd amino acid (X33) from the amino acid of the N-terminal is an arbitrary amino acid.
従来技術、競合技術の概要(英語) BACKGROUND ART
Bodily fluids such as blood or plasma from the component, the main body and immunoglobulin g (IgG) autoantibodies and immune complexes specifically adsorbed in removing, autoimmune disease related biological immune function for prevention of progress, alleviation of symptoms of diseases has been known a method thereof.
Can be used for such a purpose as adsorption material, is for example Patent Document 1, helix - loop - helix structure IgG IgG-type antibodies having a binding peptide to a carrier as IgG-type antibodies to bind to the adsorbent is disclosed. In addition, also non-patent document 1, helix - loop - helix structure having the same IgG binding peptides disclosed.
However, these IgG IgG-binding peptide binding is still cannot be said to be sufficient, further IgG-type antibodies and a high binding property is demanded.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OSAKA PREFECTURE UNIVERSITY
  • 発明者(英語)
  • FUJII Ikuo
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close